S294
Clinical - Breast
ESTRO 2026
median range of CTV change during radiation was 2.4% (range: -2.6%-9.8%). Median and range of Dmax, V105% and V108% were 27.95 Gy (27.63-28.12 Gy), 1.7% (0-12.2%), 0 (0-0.6%). During radiation, 28.5% of patients reported pain and one patient reported fatigue. No skin toxicity was reported. With a median follow-up of 13 months (range 6-24), 2 patients continued to have grade 1 pain and 2 continued to have grade 1 hyperpigmentation. In terms of cosmetic outcome, 86% were satisfied. 1 patient underwent revision two months after finishing radiation and another patient developed keloids along the incision. Physician-reported outcome showed asymmetry in 3 patients and grade 2 fibrosis in 3 patients. None of the patients had local or distant recurrence. Conclusion: This cohort shows satisfactory cosmetic outcome in patients with oncoplastic surgery who underwent adaptive ultrafractionated WBI. Oncoplastic surgery did not cause any significant delay in radiation. Future study is examining patient-reported outcome using validated questionnaires References: 1- Metz G, Snook K, Sood S, et al. Breast Radiotherapy after Oncoplastic Surgery-A Multidisciplinary Approach. Cancers (Basel). 2022 Mar 25;14(7):16852- Brunt AM, Haviland JS, Wheatley DA, et al. FAST- Forward Trial Management Group. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT. Health Technol Assess. 2023 Nov;27(25):1-17 Keywords: Adaptive, ultrafractionated, oncoplastic surgery Digital Poster 3196 Clinicopathologic Features and Survival Outcomes of Male Breast Cancer: A 10-Year Institutional Experience Alysson M. Paredes 1 , Ana C. Ahumada 1 , Mizada M. Mohamed 1 , Antonio D. De la Peña 1 , Veronica M. Mogollon 1 , Axel Villar 1 , Jose D. Miranda 2 1 Radiooncologia, Hospital Universitario, Monterrey, Mexico. 2 Radiooncologia, UBA, Buenos Aires, Argentina Purpose/Objective: IntroductionMale breast cancer (MBC) is a rare malignancy, representing approximately 1% of all breast cancer cases. Due to its low incidence, current treatment recommendations are primarily extrapolated from female populations, resulting in gaps in evidence specific to men. Understanding local epidemiologic and clinicopathologic patterns is crucial for improving diagnosis and individualized care,
VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30 Gy in five daily fractions. Clin Transl Oncol. 2020;22(10):1802-1808. doi:10.1007/s12094-020-02319-53) Leonardi MC, et al. Hypofractionated Partial Breast Reirradiation in the Conservative Retreatment of Breast Cancer Local Recurrence. Pract Radiat Oncol. 2025;15(1):31-47. doi:10.1016/j.prro.2024.07.003 Keywords: Re-irradiation, Partial breast irradiation, VMAT Outcomes of adaptive ultrafractionated whole breast irradiation in patients with oncoplastic surgery Mona Arbab, David Parsons, Weiguo Lu, Prasanna Alluri, Narine Wandrey, Dillon Li, Anna Chung, Cynthia Tye, Justin Visak, Mu-Han Lin, Asal Rahimi Radiation Oncology, UT Southwestern, Dallas, USA Purpose/Objective: Hypofractionated whole breast irradiation (WBI) has been recommended for all patients irrespective of oncoplastic surgery [1]. Ultrahypofractionated regimen has now become the standard of care [2], and with increased availability of adaptive radiation, a cohort of breast patients who underwent oncoplastic surgery and were treated with daily online adaptive radiotherapy (ART) has been followed at our institute to determine the adverse events and cosmetic outcome. Material/Methods: Digital Poster 3179 All Patients with oncoplastic surgery in this cohort who were treated between March 2023 and March 2025 were included in this abstract. Daily ART was done using a cone-beam computed tomography (CBCT) based unit. The clinical target volume (CTV) was defined per Fast-Forward regimen [2]. The planning target volume (PTV) was a 3 mm uniform expansion cropped out of body-5 mm. The adverse events, cosmetic outcomes, and physician-reported outcomes were determined from patients’ charts. Common terminology criteria for adverse events (CTCAE) version 5 were used. Results: 21 patients were included. The mean age was 61 (range: 41-86). 76% had ductal pathology, 57% had right breast cancer. The grade distribution was as follows: 48% were grade 1 followed by 38% grade 2 , and 14% grade 3. 71% had T1 and all were N0. 95% were hormone receptor positive, Her2 negative. All had negative margins. Mean weight of breast tissue removed was 268 grams (range: 30-772). Median time from surgery to simulation was 46 days. Only one patient had significant delay due to a hematoma. The
Made with FlippingBook - Share PDF online